B+
Bull case
20%
Probability
Target price
$9.00
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
BIOA
BioAge LabsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
BioAge reported $381.3 million of cash, cash equivalents and marketable securities at June 30, 2026 and estimated funding through 2029. Successful QUELL-CV data could strengthen the case for BGE-102 while QUELL-DME offers a later clinical-outcome test.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Higher BGE-102 trial spending may erode the June 30 cash balance despite management's then-current runway estimate. [#SEC-8K-2026-08-05] https://www.sec.gov/Archives/edgar/data/1709941/000119312526335368/bioa-ex99_1.htm
Momentum
2
Value
57
Sentiment
42
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.80 · Bull $9.00 · Bear $2.00Analysis 2026-10-17; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $32.56
Why
Momentum2 · Δ7d +0.3
Value57 · Δ7d -0.0
Sentiment42 · Δ7d -6.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • Higher BGE-102 trial spending may erode the June 30 cash balance despite management's then-current runway estimate. [#SEC-8K-2026-08-05] https://www.sec.gov/Archives/edgar/data/1709941/000119312526335368/bioa-ex99_1.htm
- • Low coverage and loose peer comparability make target prices and event-reaction estimates especially uncertain.
- • Biomarker improvement may not translate into patient benefit.
Catalyst clock
2026-12-31
QUELL-CV Phase 2 topline data
Lead driver: Value · See fundamentals
Momentum
2
8% active weight
Current posture
7d trendFlat
Δ7d
+0.3
Δ21d
+0.2
Value
57
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-1.2
Sentiment
42
45% active weight
Current posture
7d trendSoftening
Δ7d
-6.3
Δ21d
-22.1
Why this grade
Composite grade D. Momentum 2.0 / Value 56.9 / Sentiment 42.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-17. Scenario method
B
Base case
35%
Probability
Target price
$4.80
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
Most likely
B-
Bear case
45%
Probability
Target price
$2.00
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$229.03M
Beta
-
Shares Out
45.9M
P/E (TTM) · Derived
-2.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.23
Rev YoY
+1.6%
EPS YoY
-3.2%
Gross Margin
+97.6%
Op Margin
-1026.3%
Net Debt
-$275.54M
Current Ratio
17.19
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data